Published in:
01-01-2020 | Human Immunodeficiency Virus | Concise Research Report
Missed Opportunity for HIV Prevention Among a High-Risk Population of Women Experiencing Intimate Partner Violence
Authors:
Melissa E. Dichter, PhD, MSW, Shannon N. Ogden, MPH, Kylee J. Clyatt, MD, Christopher B. Roberts, MPH
Published in:
Journal of General Internal Medicine
|
Issue 1/2020
Login to get access
Excerpt
HIV pre-exposure prophylaxis (PrEP), a daily pill combining two antiretroviral agents, tenofovir disoproxil fumarate/emtricitabine (TDF/FTC), has been shown to be effective in preventing HIV transmission in men and women and is recommended for those at increased risk of HIV.
1 Experience of intimate partner violence (IPV) increases HIV risk for women,
2 and women receiving care in the Veterans Health Administration (VHA) experience substantial rates of IPV.
3 Given this risk and the availability of PrEP as a prevention tool in VHA, we sought to examine the association between recent IPV exposure disclosed to VHA providers through routine screening and HIV diagnosis, testing, and PrEP prescriptions among this population. …
